Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

DENTSPLY SIRONA Inc (NASDAQ:XRAY)

Dividend Yield: 4.98%

• UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $24 to $23 on Oct. 28, 2025. This analyst has an accuracy rate of 68%.
• Stifel analyst Jonathan Block maintained a Hold rating and slashed the price target from $19 to $17 on Aug. 8, 2025. This analyst has an accuracy rate of 72%.
• Recent News: DENTSPLY SIRONA will host an investor conference call and live webcast on Thursday, Nov. 6, to discuss third-quarter results.
• Benzinga Pro’s real-time newsfeed alerted to latest XRAY news.

Merck & Co Inc (NYSE:MRK)

• Dividend Yield: 3.74%
• Citigroup analyst Geoff Meacham reinstated a Neutral rating and raised the price target from $84 to $95 on Oct. 13, 2025. This analyst has an accuracy rate of 70%.
• Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and slashed the price target from $97 to $90 on July 30, 2025. This analyst has an accuracy rate of 69%
• Recent News: On Oct. 30, Merck posted better-than-expected quarterly earnings.
• Benzinga Pro's real-time newsfeed alerted to latest MRK news

Viatris Inc (NASDAQ:VTRS)

• Dividend Yield: 4.67%
• Piper Sandler analyst David Amsellem reiterated a Neutral rating and cut the price target from $14 to $10 on March 5, 2025. This analyst has an accuracy rate of 77%.
• B of A Securities analyst Jason Gerberry maintained an Underperform rating and lowered the price target from $11 to $10 on Feb. 28, 2025. This analyst has an accuracy rate of 62%.
• Recent News: Viatris will to report third quarter financial results on Nov. 6.
• Benzinga Pro’s real-time newsfeed alerted to latest VTRS news

Read More:

• Top Wall Street Forecasters Revamp Amazon Expectations Ahead Of Q3 Earnings

Photo via Shutterstock